CLAIMS

1. A crystalline sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid ~~and pharmaceutically acceptable solvates thereof~~.

2. A pharmaceutical composition comprising the crystalline sodium~~a therapeutically effective amount of a~~ salt of~~as defined in~~ claim 1 and a pharmaceutically acceptable carrier.

3. The~~A~~ pharmaceutical composition according to claim 2, wherein the composition further comprises at least~~therapeutically effective amount of~~ one ~~or more~~ other therapeutic agents.

4. The pharmaceutical composition of claim 3, wherein the at least one other therapeutic agent is selected from:

a) Anti-TNF-alpha monoclonal antibodies ~~such as Infliximab, Certolizumab pegol, Golimumab, Adalimumab and AME-527 from Applied Molecular Evolution~~,

b) TNF-alpha Antagonists ~~such as Etanercept, Lenercept, Onercept and Pegsunercept~~,

c) Calcineurin (PP-2B) Inhibitors-/-INS Expression Inhibitors ~~such as cyclosporine A, Tacrolimus and ISA-247 from Isotechnika~~,

d) IL-1 Receptor Antagonists ~~such as Anakinra and AMG-719 from Amgen~~,

e) Anti-CD20 monoclonal antibodies ~~such as Rituximab, Ofatumumab, Ocrelizumab and TRU-015 from Trubion Pharmaceuticals~~,

f) p38 Inhibitors ~~such as AMG-548 (from Amgen), ARRY-797 (from Array Biopharma), Chlormethiazole edisylate, Doramapimod, PS-540446 (from BMS), SB-203580, SB-242235, SB-235699, SB-281832, SB-681323, SB-856553 (all from GlaxoSmithKline), KC-706 (from Kemia), LEO-1606, LEO-15520 (all from Leo), SC-80036, SD-06 (all from Pfizer), RWJ-67657 (from R.W. Johnson), RO-3201195, RO-4402257 (all from Roche), AVE-9940 (from Aventis), SCIO-323, SCIO-469 (all from Scios), TA-5493 (from Tanabe Seiyaku), and VX-745 and VX-702 (all from Vertex)~~,

g) NF-kappaB (NFKB) Activation Inhibitors ~~such as Sulfasalazine and Iguratimod~~,

h) Dihydrofolate Reductase (DHFR) Inhibitors ~~such as Methotrexate, Aminopterin and CH-1504 from Chelsea~~,

i~~n~~) JAK3 Inhibitors ~~such as CP690550 (tasocitinib) from Pfizer~~,

j~~p~~) MEK inhibitors ~~such as ARRY-142886, ARRY-438162 (all from Array Biopharma), AZD-6244 (from AstraZeneca), PD-098059, PD-0325901 (all from Pfizer)~~,

k~~r~~) S1P1 agonists ~~such as Fingolimod, CS-0777 from Sankyo and R-3477 from Actelion~~,

lhh) Interferons comprising Interferon beta 1a ~~such as Avonex from Biogen Idec, CinnoVex from CinnaGen and Rebif from EMD Serono, and Interferon beta 1b such as Betaferon from Schering and Betaseron from Berlex~~,

~~(ii) Inmunomodulators suchs as BG-12 (fumaric acid derivative) from Biogen Idec/Fumapharm AG; laquinimod (Teva and Active Biotech) or glatiramer acetate (Teva), and~~

n~~(jj)~~ Adenosine aminohydrolase inhibitors ~~such as Cladribine from Merck Serono~~.

5. A combination comprising the crystalline sodiuma salt of~~as defined in~~ claim 1 and at least one ~~or more~~ other therapeutic agents~~, as defined in claim~~ 4selected from:

a) Anti-TNF-alpha monoclonal antibodies,

b) TNF-alpha Antagonists,

c) Calcineurin (PP-2B) Inhibitors/INS Expression Inhibitors,

d) IL-1 Receptor Antagonists,

e) Anti-CD20 monoclonal antibodies,

f) p38 Inhibitors,

g) NF-kappaB (NFKB) Activation Inhibitors,

h) Dihydrofolate Reductase (DHFR) Inhibitors,

i) JAK3 Inhibitors,

j) MEK inhibitors,

k) S1P1 agonists,

l) Interferons comprising Interferon beta 1a,

m) Inmunomodulators, and

n) Adenosine aminohydrolase inhibitors.

~~6. A salt according to claim 1, a pharmaceutical composition according to any one of claims 2 to 4 or a combination according to claim 5 for use in the treatment of a pathological condition or disease susceptible to amelioration by inhibition of dihydroorotate dehydrogenase.~~

~~7. A salt, a pharmaceutical composition or a combination according to claim 6 wherein the pathological condition or disease is selected from rheumatoid arthritis, psoriatic arthritis, ankylosing spondilytis, multiple sclerosis, Wegener's granulomatosis, systemic lupus erythematosus, psoriasis and sarcoidosis.~~

~~8. Use of a salt according to claim 1, a pharmaceutical composition according to any one of claims 2 to 4 or a combination according to claim 5 for the manufacture of a medicament for the treatment of a pathological condition or disease as defined in claims 6 or 7.~~

~~9. A method of treatment of a subject afflicted with a pathological condition or disease as defined in claim 6 or 7, which comprises administering to said subject an effective amount of a salt according to claim 1, a pharmaceutical composition according to any one of claims 2 to 4 or a combination according to claim 5.~~